Genscript hits 4-week high on associate's promising blood cancer cell therapy
BUZZ-Genscript hits 4-week high on associate's promising blood cancer cell therapy ** Shares of Genscript Biotech Corp 1548.HK jump 28.5% to HK$15.6, their highest level since May 8, and on course to snap a four-session slide
** Stock last up 17.8%, on track for biggest one-day pct rise since July 2024
** Co says associate Legend Biotech Corp LEGN.O will announce promising preliminary clinical data of its blood cancer therapy at European Hematology Association 2026 Congress in Sweden in mid-June
** Legend Biotech's experimental cell therapy shows early signs that its approach of generating disease-fighting cells within patients may work for a type of blood cancer
** U.S.-listed stock of Legend Biotech soared 42.2% on Tuesday
** YTD, Genscript stock up 16.2%, Legend Biotech up 66.9%, while Hang Seng Biotech Index .HSBIO down 10.3%
(Reporting by Donny Kwok)
Recent news on Legend Biotech
See all newsGenscript hits 4-week high on associate's promising blood cancer cell therapy
U.S. STOCKS ON THE MOVE-Hewlett Packard, Alphabet, Fulcrum
U.S. STOCKS ON THE MOVE-Hewlett Packard, Alphabet, Philip Morris
Legend's experimental cell therapy shows promise in blood cancer patients (updated)
Legend Biotech rises after blood cancer cell therapy shows promise